Life settlement mortality improvement trends 2026: SOA MP-2021 status, LE recovery, and buy-side IRR sensitivity.
Most mortality articles cover actuarial methodology. This article connects SOA mortality improvement updates, post-pandemic life expectancy recovery, and the troubling age 80+ trend to specific buy-side IRR implications and LE estimate sensitivity for institutional life settlement investors.
U.S. life expectancy returned to pre-pandemic levels in 2024 after the 2020-2021 COVID disruption, but the Society of Actuaries (SOA) has not updated its mortality improvement scale beyond MP-2021 due to data interpretation uncertainty about whether pandemic-era mortality represents transient distortion or structural shift. For life settlement buy-side investors, the practical implication is that LE estimates from recognized underwriting firms (21st Services, ISC, Fasano, Predictive Resources) reflect this uncertainty — and 6-24 month LE estimate variance materially affects realized IRR. A 12-month LE extension typically compresses unlevered IRR by 200-400 basis points on a representative $500K face value position; the 80+ age cohort that dominates life settlement supply requires particular sensitivity analysis. Invest in life settlements through HYV in the institutional segment where mortality improvement sensitivity is built into every pre-acquisition LE analysis.
Mortality improvement is the secular trend toward longer life expectancy across populations. For most asset classes it operates as background context; for life settlement investors it operates as the central determinant of portfolio returns. After more than two decades executing buy-side LE analysis across hundreds of transactions through normal mortality cycles, the COVID disruption, and the post-pandemic recovery, the framework below organizes what institutional investors need to understand about the current mortality landscape and the operational adjustments that disciplined buy-side construction applies.
Why mortality improvement is central to life settlement returns
Life settlement investment returns derive from a structurally simple equation: the buyer acquires a policy at a discount to face value, funds premiums through the projected life expectancy, and receives the death benefit at policy maturity (the insured's death). The realized IRR depends on three operational variables — purchase price, premium load, and timing of death benefit receipt. Of these three, timing of death benefit receipt is the single most consequential variable and the only one outside the buyer's direct control.
Mortality improvement affects this timing variable structurally. When the population experiences longer life expectancies than projected, individual death benefits arrive later than projected, premiums accumulate longer than projected, and realized IRR compresses below projection. The mechanism operates regardless of carrier credit, policy structure, or transaction quality — it is the structural risk that distinguishes life settlement investing from most other alternative asset classes.
The buy-side response to mortality improvement is operational: portfolio diversification across multiple insureds smooths idiosyncratic LE variance, but secular mortality improvement affects the entire portfolio simultaneously. A 6-month population-wide LE extension affects 20 portfolio positions in approximately the same direction simultaneously. Diversification within the portfolio reduces idiosyncratic risk but does not reduce systemic mortality improvement risk; portfolio construction must address the secular trend separately.
The 2020-2026 mortality shifts timeline
The past six years have produced the most volatile mortality data of the post-WWII era. The timeline below organizes the key events that affect current LE estimation and buy-side allocation decisions.
COVID excess mortality peak
Approximately 1.37M U.S. excess deaths through February 2020-December 2022 per CDC and academic studies. Significant compression of life expectancy at all ages with disproportionate impact on 65+ and Black/Hispanic populations.
SOA freezes scale at MP-2021
SOA's Retirement Plans Experience Committee (RPEC) updates mortality improvement scale to MP-2021. Subsequently, SOA pauses scale updates due to data interpretation uncertainty about whether pandemic-era mortality represents transient distortion or structural shift in long-term improvement trajectory.
LE recovery begins
U.S. life expectancy starts rising in 2022 after the 2020-21 declines. Recovery patterns vary materially by demographic subgroup. Insurance industry mortality experience for in-force policies begins normalizing toward pre-pandemic patterns through 2023.
Pre-pandemic LE largely achieved
U.S. life expectancies in 2024 returned approximately to 2019 pre-pandemic levels for males and nearly fully recovered for females. Standard errors of 0.008-0.012 years at birth suggest the increases reflect genuine population-level gains rather than statistical noise.
SOA AG38/VM20 mortality improvement scale
SOA's Mortality Improvement Life Working Group releases improvement factors by gender and attained age for use with 2008 VBT and 2015 VBT under AG-38 statutory framework. Adopted by NAIC's Life Actuarial Task Force. Material development for insurance industry actuarial work; less direct application to life settlement buy-side analysis.
Pub-2016 tables final release
Final Pub-2016 Public Retirement Plans Mortality Tables replace Pub-2010. Present values decline 1.0-3.3% males / 0.3-1.4% females depending on job category and age, reflecting modest mortality improvement relative to prior tables. Five-year update cycle per SOA standard practice.
Age 80+ trend concerns surface
SOA researchers publicly note "troubling" mortality trends in age 80+ cohorts. Swiss Re Research Institute late-2024 report concludes excess mortality may persist for as long as another decade. Industry actuaries seek improved data on the older-age mortality patterns most relevant to life settlement supply.
Current operational landscape
Buy-side LE underwriting firms calibrate methodology to recovered post-pandemic mortality with attention to age 80+ cohort uncertainty. Institutional investors apply LE haircuts and sensitivity analysis across pre-acquisition modeling. SOA mortality improvement scale update beyond MP-2021 anticipated but not yet released as of publication.
Three structural observations about the timeline matter operationally. First, the SOA's decision to freeze MP-2021 reflects genuine uncertainty about whether pandemic-era data represents transient distortion or structural shift. Buy-side LE estimates produced during this period carry methodology uncertainty beyond their normal confidence intervals.
Second, the 2024 LE recovery is broadly favorable to life settlement investors on a portfolio basis — population-level LE returning to pre-pandemic levels means the structural improvement trend that compressed buy-side IRR over decades has reasserted itself. But the recovery pattern varies materially by demographic subgroup, and life settlement supply concentrates in the age 80+ cohort where uncertainty remains highest.
Third, the age 80+ mortality concern is the most consequential current dynamic for life settlement specifically. The cohort that dominates supply (typically 78-92 age range at acquisition) requires careful underwriting attention and conservative LE estimation given the data uncertainty signaled by SOA actuaries.
Current mortality improvement scale published by Society of Actuaries; no update beyond MP-2021 released as of 2026 publication due to data interpretation uncertainty about whether COVID-era mortality represents transient distortion or structural shift in long-term improvement trajectory. See SOA Mortality & Longevity Research for current research streams.
LE estimate sensitivity — IRR impact by shift
The practical question for buy-side investors is: what does a 6-month, 12-month, or 24-month LE shift do to realized IRR? The table below models the impact on a representative $500K face value position acquired for $156,800 with 60-month LE projected base case at 14% unlevered IRR. The base case is the same parameter set used in our pricing math article.
LE shift sensitivity on unlevered IRR
Three observations about the sensitivity table deserve emphasis. The IRR compression is non-linear. A 6-month shift produces approximately 150bp compression; doubling the shift to 12 months produces 300bp; quadrupling to 24 months produces 550bp. The accelerating compression reflects the combined effect of delayed cash flow timing and accumulating premium load over the extended period.
Portfolio-level mortality improvement creates correlated exposure across positions. A 12-month population-wide LE extension would affect every portfolio position in approximately the same direction simultaneously. A 20-position portfolio facing 12-month LE extension across all positions would experience approximately 300bp IRR compression — not the diversification-smoothed exposure that idiosyncratic LE variance would produce.
The sensitivity asymmetry favors short-LE positions. A position with 36-month LE projected is less sensitive to 6-month extension than a position with 84-month LE projected because the extension represents a smaller proportional change. Portfolios concentrated in shorter-LE positions have lower mortality improvement sensitivity than portfolios concentrated in longer-LE positions.
The age 80+ trend and life settlement-specific implications
Life settlement supply concentrates structurally in the age 80+ insured cohort — the cohort where current mortality data is most uncertain and where SOA actuaries have publicly noted concerning trends. Three operational implications follow.
- LE underwriting methodology evolution. The recognized buy-side LE firms (21st Services, ISC, Fasano, Predictive Resources, AVS) actively monitor age 80+ mortality data and adjust methodology as evidence emerges. Buy-side investors should verify the methodology vintage of LE estimates received and request updated estimates for older underwriting reports before significant transactions.
- Conservative haircut application. Institutional buyers typically apply 0-15% conservative LE haircut beyond the underwritten estimate to account for methodology uncertainty in the older-age cohorts. The haircut compresses projected IRR but provides downside protection against systematic LE extension.
- Vintage diversification. Spreading acquisition timing across multiple periods reduces concentration in a single mortality interpretation regime. Acquisitions executed during the 2020-21 uncertainty period reflect different methodology than acquisitions executed in the 2024-26 recovery period; portfolio vintage diversification reduces systematic methodology risk.
- Cohort-aware portfolio construction. Concentration in any single insured-age cohort (e.g., all positions on 82-85 year-old insureds) creates exposure to cohort-specific mortality trends. Portfolio construction across multiple age cohorts reduces sensitivity to any single cohort's mortality experience deviation.
- Forward-looking scenario modeling. Institutional investors model scenarios consistent with continued mortality improvement (favorable to life settlement returns broadly) plus scenarios consistent with sustained excess mortality in older cohorts (unfavorable but offset by shorter LE outcomes). Two-sided scenario modeling produces better-calibrated allocation decisions than reliance on single point estimates.
For accredited investors who invest in life settlement policies through HYV, mortality sensitivity analysis is built into every pre-acquisition opportunity file. LE methodology vintage is documented, conservative haircut application is shown explicitly, and portfolio-level mortality improvement scenario analysis is available for accredited investors building multi-position allocations.
Browse vetted life settlement opportunities
HYV opportunities include LE methodology vintage documentation, conservative haircut analysis, and portfolio-level mortality improvement scenario modeling for accredited investor review.
Browse the platformBuy-side adjustment strategies
The framework above produces five operational adjustment strategies that institutional buy-side investors apply to mortality improvement risk management. Each strategy addresses a distinct dimension of the underlying risk.
- Strategy 1 — LE haircut application. Apply conservative LE haircut (typically 5-15%) beyond the underwritten estimate for age 80+ positions. Compresses projected IRR by 100-200 basis points but provides material downside protection against systematic LE extension.
- Strategy 2 — Duration shortening preference. Concentrate acquisitions in shorter-LE positions (36-60 month projected) where mortality improvement sensitivity is structurally lower. Sacrifices some return upside in favor of reduced systematic mortality risk.
- Strategy 3 — Vintage diversification. Spread acquisition timing across multiple periods rather than concentrating deployment in a single quarter. Reduces concentration in a single LE methodology interpretation regime.
- Strategy 4 — Cohort diversification. Balance portfolio across multiple insured-age cohorts (e.g., not all 82-85 year-olds, but mix of 78-82, 82-86, 86+) to reduce sensitivity to any single cohort's mortality experience deviation.
- Strategy 5 — Scenario modeling discipline. Model two-sided scenarios consistent with continued mortality improvement AND sustained excess mortality at older ages. Calibrate allocation sizing based on the unfavorable scenario tolerance rather than central case projection.
The five strategies operate together rather than in isolation. Institutional buy-side construction typically applies all five simultaneously as standard portfolio discipline. The cost is compressed projected returns relative to central-case modeling; the benefit is more resilient realized returns across the actual distribution of mortality outcomes.
Invest in life settlements with mortality sensitivity transparency
HYV opportunities incorporate the five buy-side adjustment strategies into every pre-acquisition opportunity file — LE haircut documentation, duration analysis, vintage tracking, cohort balance, and two-sided scenario modeling.
Mortality improvement is the secular trend toward longer life expectancy across populations. The current Society of Actuaries mortality improvement scale is MP-2021, with the SOA having paused subsequent updates due to data interpretation uncertainty about whether 2020-2021 pandemic-era mortality represents transient distortion or structural shift. The 2024 individual life mortality improvement scale released by SOA's Mortality Improvement Life Working Group for use with AG38/VM20 statutory framework provides gender and attained age improvement factors adopted by the NAIC's Life Actuarial Task Force; this scale applies primarily to insurance industry actuarial work rather than life settlement buy-side analysis. The final Pub-2016 Public Retirement Plans Mortality Tables released by SOA RPEC in May 2025 replace Pub-2010 with present values declining 1.0-3.3% for males and 0.3-1.4% for females. Industry mortality research is published by the Society of Actuaries Research Institute; U.S. population mortality data is published by the CDC National Center for Health Statistics.
U.S. life expectancy returned approximately to 2019 pre-pandemic levels for males in 2024 and nearly fully recovered for females, per academic research published on medRxiv in May 2025 with Chiang method standard errors of 0.008-0.012 years at birth. Approximately 1.37 million U.S. excess deaths occurred between February 2020 and December 2022 per CDC and academic analyses. The Swiss Re Research Institute late-2024 report concluded that excess mortality may persist for as long as another decade. SOA actuaries have publicly noted concerning trends in age 80+ mortality cohorts — the cohort that dominates life settlement supply, requiring particular sensitivity in LE underwriting methodology and buy-side haircut application. The recognized buy-side LE underwriting firms include 21st Services, ISC Services, Fasano Associates, Predictive Resources, and AVS, each calibrating methodology to evolving mortality data.
For life settlement buy-side investors, mortality improvement affects realized IRR through delayed death benefit receipt and accumulating premium load. A 12-month population-wide LE extension typically compresses unlevered IRR by approximately 300 basis points on a representative $500K face value 60-month LE position; 6-month and 24-month shifts produce approximately 150bp and 550bp compression respectively. Buy-side adjustment strategies include conservative LE haircut application (5-15% beyond underwritten estimate), duration shortening preference (shorter-LE positions less sensitive to extension), vintage diversification (acquisition timing spread across multiple periods), cohort diversification (insured age balance across multiple cohorts), and two-sided scenario modeling discipline. Industry research and methodology context is published by the Life Insurance Settlement Association (LISA). Federal investor accreditation under SEC Rule 501 of Regulation D applies to all life settlement direct-ownership investments.
Invest in life settlements with mortality sensitivity built in
HYV pre-acquisition diligence includes LE methodology vintage documentation, conservative haircut analysis, vintage tracking, cohort balance, and two-sided scenario modeling for accredited investor portfolio construction.
Frequently asked questions
What is mortality improvement and why does it matter for life settlements?
Mortality improvement is the secular trend toward longer life expectancy across populations driven by medical advances, healthier lifestyles, and reduced cause-specific mortality. For life settlement buy-side investors, mortality improvement is the central structural risk because returns depend on death benefit receipt timing. When the population experiences longer life expectancies than projected, death benefits arrive later than projected, premiums accumulate longer than projected, and realized IRR compresses. Unlike most alternative asset classes where mortality improvement operates as background context, for life settlements it operates as the dominant return determinant — making mortality improvement analysis central rather than peripheral to investment decisions.
What is SOA MP-2021 and why hasn't it been updated?
MP-2021 is the Society of Actuaries' mortality improvement scale published in 2021. The scale provides factors that adjust base mortality rates over time to reflect expected secular improvement. The SOA has not released subsequent scale updates beyond MP-2021 due to data interpretation uncertainty about whether 2020-2021 pandemic-era mortality represents transient distortion (which would not affect long-term improvement trajectory) or structural shift (which would). The pause reflects appropriate methodological caution rather than complacency. The 2024 individual life mortality improvement scale for AG38/VM20 applies more narrowly to insurance industry statutory actuarial work. For life settlement buy-side analysis, the methodology uncertainty signaled by the SOA scale freeze warrants extra conservatism in LE estimation and portfolio construction.
How much does a 12-month LE extension affect realized IRR?
On a representative $500K face value position with 60-month base LE at 14% unlevered IRR, a 12-month LE extension typically compresses realized IRR by approximately 300 basis points (to roughly 11%). The compression operates through two mechanisms: delayed death benefit receipt (the discount rate compounds over the additional 12 months) and accumulated premium load (an additional year of $30K premium). The IRR compression is non-linear — a 6-month shift produces 150bp compression, doubling to 12 months produces 300bp, and a 24-month shift produces 550bp compression. Portfolio-level mortality improvement creates correlated exposure across positions, meaning a population-wide LE extension affects every portfolio position in approximately the same direction simultaneously.
Why is the age 80+ cohort particularly relevant to life settlements?
Life settlement supply concentrates structurally in the age 80+ insured cohort — typically 78-92 age range at acquisition. SOA actuaries have publicly noted concerning trends in age 80+ mortality data, and the cohort is where current mortality methodology carries the highest uncertainty. The combination — life settlement supply concentration plus methodology uncertainty in exactly that cohort — makes age 80+ mortality the single most consequential current dynamic for buy-side investors. Operational implications include conservative LE haircut application (typically 5-15% beyond underwritten estimate), preference for verified methodology vintage from recognized LE firms, and portfolio diversification across multiple insured-age cohorts rather than concentration in a single age band.
Did COVID excess mortality help life settlement returns?
COVID-era excess mortality produced approximately 1.37 million U.S. excess deaths between February 2020 and December 2022. For life settlement positions held during this period, the increased mortality rate produced some portfolios with realized IRR exceeding projection as death benefits arrived earlier than expected. However, the buy-side investor experience was mixed — pre-pandemic LE estimates did not anticipate the disruption, and methodology uncertainty during the recovery period created its own complications. The structural lesson is that mortality improvement risk operates in both directions: faster mortality enhances returns; slower mortality compresses them. Disciplined buy-side construction calibrates expectations to long-term mortality patterns rather than short-term disruption windfalls or compressions.
How do buy-side LE underwriting firms adjust to mortality changes?
The recognized buy-side LE underwriting firms — 21st Services, ISC Services, Fasano Associates, Predictive Resources, AVS — actively monitor mortality data and adjust methodology as evidence emerges. Each firm maintains proprietary methodology with periodic recalibration to recent mortality experience. For institutional buy-side investors, methodology vintage matters operationally — LE estimates from 2019 underwriting reports reflect pre-pandemic methodology; estimates from 2024 reports reflect post-recovery methodology with attention to age 80+ uncertainty. Pre-acquisition diligence should verify methodology vintage and consider requesting updated estimates for older underwriting reports before significant transactions. Most institutional acquisitions use two independent LE estimates from different firms with appropriate variance analysis.
What is a conservative LE haircut and when is it appropriate?
A conservative LE haircut is a buy-side practice of extending the underwritten LE estimate by a percentage (typically 5-15%) for pricing and IRR projection purposes. For example, an underwritten 60-month LE with 10% haircut would be modeled at 66 months for IRR projection. The haircut application compresses projected IRR by approximately 100-200 basis points but provides material downside protection against systematic LE extension. Institutional buyers typically apply higher haircuts to age 80+ positions where methodology uncertainty is greatest, lower haircuts to age 70-79 positions where methodology confidence is higher. The haircut is a tradeoff between projected return optimization and downside protection; disciplined buy-side construction generally errs toward conservatism.
How does HYV incorporate mortality improvement analysis?
High Yield Vault incorporates mortality improvement analysis into every pre-acquisition opportunity file. Specific documentation includes: LE methodology vintage identification for the underwriting reports received; conservative haircut application analysis showing pricing under base LE and haircut scenarios; portfolio-level mortality sensitivity modeling for accredited investors building multi-position allocations; cohort diversification analysis showing balance across insured-age bands; and two-sided scenario modeling consistent with both continued mortality improvement and sustained excess mortality scenarios. Across 21 years of practice and 438 accredited investors served, HYV's framework reflects mortality improvement as the central structural risk that distinguishes institutional discipline from amateur execution.
